Table 3.
Multivariate Analysis of Factors Associated with Disease-Free Survival.
| Characteristics | Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P | HR | (95% CI) | P | HR | (95% CI) | P | HR | (95% CI) | |
| Irinotecan | |||||||||
| Yes | .45 | 1.17 | .78 – 1.74 | .87 | 1.03 | .68 – 1.57 | .86 | 1.03 | .68 – 1.58 |
| No | |||||||||
| Months of chemotherapy | |||||||||
| ≤3 | |||||||||
| >3 | .028 | 1.52 | 1.05 – 2.22 | .043 | 1.48 | 1.01 – 2.17 | .025 | 1.55 | 1.06 – 2.28 |
| Pathologic response | |||||||||
| Complete | |||||||||
| Major | .009 | 4.72 | 1.47 – 15.14 | - | - | - | 1 | 1 | .63 – 1.57 |
| Minor | .002 | 6.33 | 1.97 – 20.31 | - | - | - | .064 | 3.61 | .93 – 13.88 |
| Tumor thickness at TNI | |||||||||
| <0.5 mm | |||||||||
| ≥0.5 mm and <5 mm | - | - | - | .015 | 2.07 | 1.15 – 3.71 | .015 | 2.03 | 1.21 – 3.32 |
| ≥5 mm | - | - | - | <.001 | 3.89 | 2.06 – 7.37 | .004 | 2.71 | 1.25 – 6.06 |
| No. of CLM | |||||||||
| <3 | |||||||||
| ≥3 | .038 | 1.60 | 1.03 – 2.50 | .037 | 1.61 | 1.03 – 2.51 | .027 | 1.55 | 1.05 – 2.28 |
| Positive margin | |||||||||
| No | |||||||||
| Yes | .011 | 2.66 | 1.25 – 5.64 | .016 | 2.50 | 1.18 – 5.30 | .014 | 2.57 | 1.21 – 5.49 |
Abbreviations: HR, hazard ratio; CI, confidence interval; TNI, tumor–normal liver interface CLM, colorectal liver metastases.
CEA was not included in the multivariate analyses because of missing data for 28 patients.
Model 1 and model 2 included all factors significant in univariate analysis except tumor thickness at TNI and pathologic response, respectively.
Model 3 included all factors significant in univariate analysis.